Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIR-101 for fatigue in Long COVID
ACTRN12625001372471Phase 2Not yet recruiting
- Sponsor
- STIR Pharma Ltd
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in post-COVID syndrome and asthenia comparing STIR-101 with Placebo (2 arms). Primary endpoints: Change in fatigue and Safety of daily STIR-101 treatment. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
naltrexone
03
Conditions
post-COVID syndromeasthenia
Beyond the preview
Go deeper on ACTRN12625001372471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001372471.